The new version of the National Medical Insurance Drug Catalogue will be implemented from January 1st. Among them, the innovative drug Agamod for treating myasthenia gravis has been included in medical insurance to improve drug accessibility. Jiang Qilong, Deputy Chief Physician of the Department of Myopathy at the First Affiliated Hospital of Guangzhou University of Chinese Medicine, stated on the 2nd that it is believed that in the coming years, the standardization and standardization of the treatment of myasthenia gravis in China will be further improved. As a rare neurological and immune disease, systemic myasthenia gravis is a chronic, autoimmune neuromuscular disease caused by dysfunction of neuromuscular junction transmission. Systemic myasthenia gravis can affect the patient's eye movement, speech, limb movement, swallowing, and respiratory function to varying degrees, leading to significant muscle weakness. "One of the hazards of this disease is that it affects the quality of life of patients. If the systemic condition is severe, it can lead to respiratory failure and endanger life." Jiang Qilong said, for example, patients cannot even do some heavy work. Once a crisis occurs, they also need to be admitted to the ICU for ventilation, and the condition is prone to relapse. For severe cases of difficult to treat, they may even be admitted to the ICU once or twice a month, This situation has a very heavy physical and psychological impact on patients, as well as an economic burden. Myasthenia gravis can generally be judged by the appearance of fluctuating symptoms, combined with electromyography repeated electrical stimulation tests, acetylcholine antibody tests, and other methods. In clinical practice, patients with myasthenia gravis have significant individualized differences, varying disease progression, and difficulty in disease management. For a long time, the treatment of patients with systemic myasthenia gravis has mainly relied on traditional drug treatment plans, including cholinesterase inhibitors, glucocorticoids, immunosuppressants, thymectomy, and traditional Chinese medicine treatment. However, traditional Western medicine treatment methods have significant shortcomings in symptom control and treatment of side effects. At present, the disease is still incurable, but standardized treatment can control symptoms and is considered a treatable disease. The emergence of innovative drugs is expected to achieve disease relief and symptom control for patients. Starting from January 1st this year, the new version of the National Medical Insurance Drug Catalogue has been implemented, and innovative drugs for treating rare diseases have attracted much attention. Aunt Chen (pseudonym) from Yangjiang, Guangdong is a 73 year old patient with myasthenia gravis. "I have been sick for more than half a year now. I have had my thymoma removed before, and although I have used steroids, immunoglobulin, etc., I still experienced repeated weakness in my limbs and breathing difficulties. After receiving innovative medicine treatment for the second time in the hospital, my overall strength improved significantly and I was discharged." Aunt Chen said that now I can reimburse my medical insurance expenses, which reduces the economic burden on the people. The new medicine also has the opportunity to be used for a long time. Jiang Qilong stated that after being included in medical insurance, the reimbursement ratio for local patients in Guangzhou ranges from 70% to 86%. According to the five treatment cycles per year, patients who meet the reimbursement criteria will have a minimum annual self paid treatment cost of over 30000 yuan after being reimbursed by medical insurance. "As the diagnosis and treatment of myasthenia gravis in China officially enters the era of evidence-based and biologically targeted therapy, further optimizing drug treatment strategies to achieve safe, effective, and precise treatment has become an important issue in clinical treatment," said Jiang Qilong. (End) (Le Xin She) (Reporter Cai Minjie)